QNCX Brendan Hannah buys $19K worth of shares
Aug 21, 2024, 11:31 PM
9.33%
What does QNCX do
Quince Therapeutics, headquartered in South San Francisco, focuses on developing EryDex for Ataxia-Telangiectasia using their AIDE technology for optimal drug delivery. Since their IPO on 2019-05-09, they aim to expand the platform’s applications beyond rare diseases.
Brendan Hannah bought 30,845 shares of QNCX on 21 August at $0.63 per share, worth a total of $19K. They now own 296,540 QNCX shares, or a 12% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.